Gemtuzumab the conjugate represents a novel development in the treatment of acute myeloid disease, specifically severe leukemic malignancy (AML). The antibody-drug joins a targeted antibody specific against the CD33 receptor found on abnormal populations of cells with a chemotherapeutic drug, resulting in targeted cell death. Hence, it offers a pos